Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
https://link.springer.com/content/pdf/10.1007/s11912-022-01241-z.pdf
Reference79 articles.
1. Joyce JA., Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Vol. 348, Science. American Association for the Advancement of Science; 2015. p. 69–74.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Vol. 12, Nature Reviews Cancer. 2012. p. 252–64.
3. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Vol. 12, Cancers. MDPI AG; 2020.
4. Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Vol. 20, Nature Immunology. Nature Publishing Group; 2019. p. 1425–34.
5. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Vol. 19, Nature Reviews Cancer. Nature Publishing Group; 2019. p. 133–50.
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study;Neoplasia;2024-11
2. Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma;Journal for ImmunoTherapy of Cancer;2024-09
3. A Retrospective Analysis of the Prognostic Factors and Adverse Events in the Treatment of Mucosal Melanoma in a Single Centre;Journal of Clinical Medicine;2024-08-13
4. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma;European Journal of Cancer;2024-08
5. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study;Journal of Thoracic Disease;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3